What is NVS's current stock price?

As of now, NVS is trading at $130.68, with a daily change of +0.33%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

NVS Stock Analysis & IQ Rating | Novartis AG

NVS

Novartis AG

$130.68

+$0.43 | +0.33%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$134

MKT CAP

$269.94B

52W Low

$96.06

VOL

$681.75K

P/E Ratio

17.87

AVG VOL

$1.74M

RSI

56.03

TREND

Uptrend

NVS Stock IQ

Login to see Novartis AG (NVS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

NVS Target Price

Login to display

Strengths

NVS Rewards

Earnings are forecast to grow

NVS Rewards

Upgraded on attractively valued

NVS Rewards

Outperform the market

NVS Rewards

Expands stock buyback program

Chart

$123.79 (+5.57%)

$128.42 (+1.76%)

$122.94 (+6.30%)

$99.22 (+31.71%)

1year

6month

3month

1month

NVS Risk Level

NVS has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

NVS Analysts Opinion

NVS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

NVS Analysts Opinion

NVS Analysts opinion is positive and it remained unchanged from the past 3 months

NVS Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

93%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

67%

100%

80%

NVS Street Sentiment

NVS Street Sentiment is extremely bullish and have positive views on the near-term outlook

NVS Performance Sentiment

Sentiments overview associated with NVS events and the stock performance.

93%

4%

Positive

Negative

42 out of 45
events present

2 out of 45
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$127.31

Resistance
Price

$121.78

Current Price Range

$132.29

Show methods +

Linked to NVS

IQ

Close Price

Change

PFE

3.94

25.73

+0.04%

AZN

4.31

93.90

+0.71%

MRK

4.03

105.66

+0.01%

SNY

4.02

49.94

-0.69%

REGN

4.20

786.18

-0.14%

NVS Latest Analysis +

Why Novartis Stock Topped the Market Today. Key PointsIt earned FDA approval for a spinal muscular atrophy drug.

Today

$130.68 | +0.33%

Activity

FDA Greenlights Novartis Gene Replacement Treatment for SMA. Novartis secures FDA approval for Itvisma a one-time gene therapy designed to boost motor function across a broad SMA patient group.

Tue Nov 25, 2025

$130.28 | +2.95%

Activity

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids Teens And Adults. On Monday the United States Food and Drug Administration (FDA) approved NVS) Itvisma (onasemnogene abeparvovec-brve) for children two years and older teens and adults with spinal muscular atrophy (SMA). The approval makes the gene replacement therapy the first and only one available for this broad population.Itvisma addresses the genetic root cause of SMA. The one-time fixed dose does not need adjustment for a

Tue Nov 25, 2025

$130.28 | +2.95%

Activity

Novartis Wins FDA Nod For Gene Replacement Therapy Itvisma To Treat Spinal Muscular Atrophy . (RTTNews) - Novartis Pharma AG (NVS) said Tuesday that the FDA has approved Itvisma for the treatment of children two years and older as well as teens and adults living with spinal muscular atrophy with a confirmed mutation in the survival motor neuron 1 (SMN1) gene.

Tue Nov 25, 2025

$130.28 | +2.95%

Activity

FDA approves Novartis Itvisma first gene therapy for SMA patients 2 and older.

Tue Nov 25, 2025

$130.28 | +2.95%

Activity

Labcorp Appoints Victor Bulto to Board of Directors. Bulto President United States of Novartis brings global healthcare leadership and growth track record to support Labcorps long-term strategy BURLINGTON N.C. Nov. 24 2025 /PRNewswire/ -- Labcorp (NYSE: LH) a global leader of innovative and comprehensive laboratory services today announced...

Mon Nov 24, 2025

$126.54 | -0.60%

Activity

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth. Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.

Fri Nov 21, 2025

$127.31 | +2.42%

Momentum

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts. NVS) projects a stronger growth trajectory through 2030 lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.The company its mid-term outlook ahead of its Meet Novartis Management event in London emphasizing higher confidence in long-term demand drivers and upcoming drug launches.The drugmaker now anticipates a rate of 5% to 6% on a

Thu Nov 20, 2025

$124.36 | -2.32%

Activity

Novartis Issues Updated Mid-term Sales Guidance. Upgrades Peak Sales Guidance For Kisqali Scemblix . (RTTNews) - Novartis (NVS) announced its mid-term guidance to 2025-2030 of a sales CAGR of 5-6% cc. The company noted that the updated outlook follows upgrade of 2024-2029 guidance to 6% cc. Also the peak sales guidance was upgraded for Kisqali and Scemblix: Kisqali raised from

Thu Nov 20, 2025

$124.36 | -2.32%

Activity

Rating

Novartis sees sales boost from key cancer drugs. Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030 on a currency-adjusted basis as sales for cancer drugs offset expiring patents.

Thu Nov 20, 2025

$124.36 | -2.32%

Activity

Potential

FAQ About NVS Stock Insights

What is NVS current stock price?

What are NVS stock strengths?

What is NVS Risk Level?

What is NVS market cap and volume?

What is NVS current Stock IQ?

Should I buy NVS stock right now?

Is NVS a Strong Buy right now?

What does a 'Strong Buy' rating mean for NVS?

What does a 'Strong Sell' rating mean for NVS?

What factors influence NVS's Stock IQ?

Explore our NVS Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored NVS Stock Strategies
Effective Risk Management

FIND US ON

Receive our NVS Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

NVS

Novartis AG

Current Price

$130.68

+$0.43 | +0.33%

52W High

$134

MKT CAP

$269.94B

52W Low

$96.06

VOL

$681.75K

P/E Ratio

17.87

AVG VOL

$1.74M

RSI

56.03

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

NVS Rewards

Earnings are forecast to grow

NVS Rewards

Upgraded on attractively valued

NVS Rewards

Outperform the market

NVS Rewards

Expands stock buyback program

Linked to NVS

Symbol

IQ

Close

Change

PFE

3.94

25.73

+0.04%

AZN

4.31

93.90

+0.71%

MRK

4.03

105.66

+0.01%

SNY

4.02

49.94

-0.69%

REGN

4.20

786.18

-0.14%

NVS Stock IQ

Login to unlock Novartis AG (NVS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$123.79 (+5.57%)

$128.42 (+1.76%)

$122.94 (+6.30%)

$99.22 (+31.71%)

1year

6month

3month

1month

NVS Analysts Opinion

NVS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

NVS Analysts Opinion

NVS Analysts opinion is positive and it remained unchanged from the past 3 months

NVS Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

93%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

67%

100%

80%

NVS Street Sentiment

NVS Street Sentiment is extremely bullish and have positive views on the near-term outlook

NVS Risk Level

NVS has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

NVS Performance Sentiment

Sentiments overview associated with NVS events and the stock performance.

93%

4%

Positive

Negative

42 out of 45
events present

2 out of 45
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$127.31

Resistance
Price

$121.78

Current Price Range

$132.29

Show methods +

NVS Latest Analysis

Why Novartis Stock Topped the Market Today. Key PointsIt earned FDA approval for a spinal muscular atrophy drug.

Today

$130.68 | +0.33%

Activity

FDA Greenlights Novartis Gene Replacement Treatment for SMA. Novartis secures FDA approval for Itvisma a one-time gene therapy designed to boost motor function across a broad SMA patient group.

Tue Nov 25, 2025

$130.28 | +2.95%

Activity

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids Teens And Adults. On Monday the United States Food and Drug Administration (FDA) approved NVS) Itvisma (onasemnogene abeparvovec-brve) for children two years and older teens and adults with spinal muscular atrophy (SMA). The approval makes the gene replacement therapy the first and only one available for this broad population.Itvisma addresses the genetic root cause of SMA. The one-time fixed dose does not need adjustment for a

Tue Nov 25, 2025

$130.28 | +2.95%

Activity

Novartis Wins FDA Nod For Gene Replacement Therapy Itvisma To Treat Spinal Muscular Atrophy . (RTTNews) - Novartis Pharma AG (NVS) said Tuesday that the FDA has approved Itvisma for the treatment of children two years and older as well as teens and adults living with spinal muscular atrophy with a confirmed mutation in the survival motor neuron 1 (SMN1) gene.

Tue Nov 25, 2025

$130.28 | +2.95%

Activity

FDA approves Novartis Itvisma first gene therapy for SMA patients 2 and older.

Tue Nov 25, 2025

$130.28 | +2.95%

Activity

Labcorp Appoints Victor Bulto to Board of Directors. Bulto President United States of Novartis brings global healthcare leadership and growth track record to support Labcorps long-term strategy BURLINGTON N.C. Nov. 24 2025 /PRNewswire/ -- Labcorp (NYSE: LH) a global leader of innovative and comprehensive laboratory services today announced...

Mon Nov 24, 2025

$126.54 | -0.60%

Activity

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth. Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.

Fri Nov 21, 2025

$127.31 | +2.42%

Momentum

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts. NVS) projects a stronger growth trajectory through 2030 lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.The company its mid-term outlook ahead of its Meet Novartis Management event in London emphasizing higher confidence in long-term demand drivers and upcoming drug launches.The drugmaker now anticipates a rate of 5% to 6% on a

Thu Nov 20, 2025

$124.36 | -2.32%

Activity

Novartis Issues Updated Mid-term Sales Guidance. Upgrades Peak Sales Guidance For Kisqali Scemblix . (RTTNews) - Novartis (NVS) announced its mid-term guidance to 2025-2030 of a sales CAGR of 5-6% cc. The company noted that the updated outlook follows upgrade of 2024-2029 guidance to 6% cc. Also the peak sales guidance was upgraded for Kisqali and Scemblix: Kisqali raised from

Thu Nov 20, 2025

$124.36 | -2.32%

Activity

Rating

Novartis sees sales boost from key cancer drugs. Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030 on a currency-adjusted basis as sales for cancer drugs offset expiring patents.

Thu Nov 20, 2025

$124.36 | -2.32%

Activity

Potential

Discover NVS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NVS. We're here to help you make informed investment decisions today.

FIND US ON

Receive our NVS Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NVS Stock trends

NVS Stock performance

NVS Stock analysis

NVS investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

NVS Stock Analysis & IQ Rating | Novartis AG

NVS Stock IQ

NVS Target Price

NVS Risk Level

NVS Analysts Opinion

NVS Street Sentiment

NVS Performance Sentiment

Technical Price Levels

Explore our NVS Stock insights

Receive our NVS Daily Alerts

NVS Stock IQ

NVS Street Sentiment

NVS Risk Level

Technical Price Levels

Discover NVS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NVS. We're here to help you make informed investment decisions today.

Receive our NVS Daily Alerts

NVS Runner Alarm